MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$3,948,675
EPS
-$0.27
Unit: Dollar
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Research and development
3,558,714
5,207,564
7,589,797
3,521,576
General and administrative
462,931
518,190
355,194
653,066
Total operating expenses
4,021,645
5,725,754
7,944,991
4,174,642
Loss from operations
-4,021,645
-5,725,754
-7,944,991
-4,174,642
Interest income
72,970
68,617
22,258
22,797
Net loss
-3,948,675
-5,657,137
-7,922,733
-4,151,845
Basic EPS
-0.27
-0.39
-0.568
-0.3
Diluted EPS
-0.27
-0.39
-0.568
-0.3
Basic Average Shares
14,621,230
14,565,230
13,956,054
13,641,384
Diluted Average Shares
14,621,230
14,565,230
13,956,054
13,641,384
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net loss
-$3,948,675
(1.90%↑ Y/Y)
Interest income
$72,970
(252.94%↑ Y/Y)
Loss from operations
-$4,021,645
(0.60%↑ Y/Y)
Total operating
expenses
$4,021,645
(-0.60%↓ Y/Y)
Research and development
$3,558,714
(1.45%↑ Y/Y)
General and
administrative
$462,931
(-13.96%↓ Y/Y)
Buy us a coffee
Greenwich LifeSciences, Inc. (GLSI)
Greenwich LifeSciences, Inc. (GLSI)